38 TESTING In the context of dermo-cosmetic compounds
targeting the skin flora exploration, this double approach allows to investigate the potential effects on the microorganism itself, as well as the response of the tissue to this infection. Within ourMicroBIOS Platform, this interesting
twofold methodological approach is extended to the study of other living bacterial strains (Staphylococcus aureus and Staphylococcus epidermidis) and yeasts (Malassezia furfur) on RHE. Those different available in vitro 3D models and associated tests offer a promising tool to speed up the research, understanding and objectivation of innovative dermo-cosmetic actives that target the skin flora.
PC
References 1. Dagnelie MA, Corvec S, Saint-Jean M, Nguyen J-M, Khammari A ,Dréno B. Cutibacterium acnes phylotypes diversity loss: a trigger for skin inflammatory process. J Eur Acad Dermatol Venereol. 2019 Dec;33(12):2340-2348
2. Beylot C, Auffret N, Poli F, Claudel J-P, Leccia M-T, Del Giudice P, Dreno B. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol. 2014, 28, 271–278
3. Zheng Jun Li, Dae Kyoung Choi, Kyung Cheol Sohn, Min Seok Seo, Hae Eul Lee, Young Lee,Young Joon Seo, Young Ho Lee, Ge Shi,
Down-regulation
4.00 3.75 3.50 3.25 3.00 2.75 2.50 2.25 2.00 1.75 1.50 1.25
1.00 0.75 0.50 0.25 0.00
-1.0 -0.5 0.0 0.5 1.0 1.5 2.0 2.5 log2 (Fold Change)
Figure 4: Gene expression analysis by TaqMan Low Density Array (TLDA) technology. Volcano plot obtained by comparison of 93 gene expression in non-colonised versus Cutibacterium acnes-colonised reconstructed human epidermis, after total RNA extraction, reverse transcription and amplification using Straticell’s TLDA referred as ‘Skin Response to Microorganisms’. Y axis: statistically significant gene expression variations defined as Log10 of the p-value set at 0.05. X axis: gene expression regulation defined as the Log2 of fold change expression set at 1. Genes involved in the skin inflammation are framed in red. Genes involved in the innate immunity are framed in green. Genes involved in the skin barrier are framed in blue
PERSONAL CARE June 2022
www.personalcaremagazine.com 3.0 3.5 4.0 4.5 5.0 5.5
2000 1800 1600 1400 1200 1000 800 600 400 200 0
*** * **
CTL
CXCL-8
DEFB4
IL-1β
Figure 3: Gene expression analysis by RT-qPCR. Histogram showing the percentage of CXCL-8, IL-1β and DEFB4 gene expression in reconstructed human epidermis colonised with Cutibacterium acnes compared to non-colonised control reconstructed epidermis (CTL)
Christos C. Zouboulis, Chang Deok Kim, Jeung Hoon Lee and Myung Im. Propionibacterium acnes Activates the NLRP3 Inflammasome in Human Sebocytes. Journal of Investigative Dermatology. 2014. 134, 2747–2756
4. Leung AKC, Barankin B, Lam JM, Leong KF, Hon KL. Dermatology: how to manage acne vulgaris. Drugs in Context. 2021;10:2021-8-6
Up-regulation
5. Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JH, Sewon Kang, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, LF Stein Gold, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74:945-73
significanr variations Not Statistically
Statistically significant variations -log10 (P-Value)
Gene expression (% compared to control)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88
